OncoMatch/Clinical Trials/NCT06057402
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Is NCT06057402 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Elranatamab for multiple myeloma.
Treatment: Elranatamab — This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Multiple Myeloma
Prior therapy
Must have received: elranatamab (elranatamab) — Parent Study
Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).
Cannot have received:
Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCHealth Poudre Valley Hospital · Fort Collins, Colorado
- UCHealth Harmony · Fort Collins, Colorado
- UCHealth Greeley Hospital · Greeley, Colorado
- Longs Peak Hospital · Longmont, Colorado
- UCHealth Longs Peak Medical Center · Longmont, Colorado
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06057402 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages